Competing Risk Survival Analysis In Patients With Symptomatic Waldenstrom Macroglobulinemia: The Impact Of Disease Unrelated Mortality And Of Rituximab-Based Primary Therapy

Efstathios Kastritis, Marie-Christine Kyrtsonis,Pierre Morel, Maria Gavriatopoulou,Evdoxia Hatjiharissi, Argirios S. Symeonidis,Amalia Vassou,Panagiotis Repousis, Sossana Delimpasi,Anastasia Sioni, Evrydiki Michalis, Michail Michael, Elina Vervessou,Michael Voulgarelis, Costantinos Tsatalas,Evangelos Terpos,Meletios A. Dimopoulos

HAEMATOLOGICA（2015）

引用 46|浏览16

暂无评分

摘要

WM is a disease of the elderly with a protracted course in many patients and a median survival of 7 to 10 years,[1][1] however, in many patients, other factors rather than WM or its treatment may be the cause of death.[2][2] Non-WM-related mortality mainly affects outcomes of elderly patients and is

查看译文

关键词

Rituximab,fludarabine,cyclophosphamide,age,prognosis,lymphoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要